Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Chronic myeloid leukemia (CML) patients with the BCR-ABL T315I mutation do not benefit from therapy with currently approved tyrosine kinase inhibitors. Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activity in cells harboring the T315I mutation. This phase 2 trial...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Cortes, Jorge, Lipton, Jeff H., Rea, Delphine, Digumarti, Raghunadharao, Chuah, Charles, Nanda, Nisha, Benichou, Annie-Claude, Craig, Adam R., Michallet, Mauricette, Nicolini, Franck E., Kantarjian, Hagop
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2012
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916583/
https://ncbi.nlm.nih.gov/pubmed/22896000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-03-415307
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars